CompletedNCT03232112
Exenatide or Placebo and Alcohol Intake in Adults With Alcohol Dependence
About this title
Read the official source — NCT03232112Medication studyAges 18–70DenmarkAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 70 years.
- Listed locations
- CopenhagenSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: August 7, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 152
- Sponsor
- Anders Fink-Jensen, MD, DMSci
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Denmark
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT03232112
- Official title
Show the full official title
Does Glucagon-like Peptide (GLP-1) Receptor Agonist Stimulation Reduce Alcohol Intake in Patients With Alcohol Dependence?
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Copenhagen
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Anders Fink-Jensen, MD, DMSci.
Did this study involve medication?
Yes. The study involved medication, including Exenatide 2 MG Injection and BD PosiFlush (saline).
Who was this study for?
Listed age limits: 18 years to 70 years.
